Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Next-Generation Oral Small-Molecule GLP-1s Unlocking Primary-Care and Emerging-Market Volume Orforglipron, GSBR-1290, and VK2735 demonstrated double-digit weight-loss efficacy in Phase 2 studies without injection-related barriers, attracting strong interest from primary-care physicians
The Phase III trial of this pipeline drug for treating type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity started on August 28, 2023
Redness that continues to spread over time is NOT normal, and can be a sign of infection (contact your doctor)
By once-weekly subcutaneous injection
US$ 28.46
US$ 28.34
US$ 22.57
